Biotechnology News and Research

RSS

Transition of oncology programme into lead optimisation triggers EUR 2.0M milestone payment to Evotec

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec.

13 Jan 2011

Antibiotic treatment may be sufficient to overcome River Blindness

The team found that a bacterium inside the worm acts as a 'disguise' for the parasite, resulting in the immune system reacting to it in an ineffective way. The bacteria protect the worm from the body's natural defences, but once the bacteria are removed with antibiotics, the immune system responds appropriately, releasing cells, called eosinophils, that kill the worm.

13 Jan 2011

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

VistaGen Therapeutics, Inc. and NuPotential, Inc. today announced that the National Heart, Lung and Blood Institute of the U.S. National Institutes of Health (NIH) has awarded to the companies a grant of approximately $500,000 to accelerate development of novel and safer approaches to generate patient-specific induced pluripotent stem (iPS) cells for regenerative medicine, drug discovery and drug rescue.

13 Jan 2011

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

MedImmune, the global biologics unit of AstraZeneca PLC and Micromet, today announced the initiation of a Phase 1 trial of MEDI-565 in patients with advanced gastrointestinal cancers. MEDI-565 is a BiTE antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express carcinoembryonic antigen.

13 Jan 2011

FDA accepts to review Fibrocell Science's azficel-T drug

Fibrocell Science, a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that the U.S. Food & Drug Administration has accepted for review the Company's complete response submission for azficel-T, proposed brand name laViv, for the treatment of moderate to severe nasolabial folds and wrinkles.

12 Jan 2011

Fruit and vegetables gives more healthy golden glow than the sun

New research suggests eating vegetables gives you a healthy tan. The study, led by Dr Ian Stephen at The University of Nottingham, showed that eating a healthy diet rich in fruit and vegetables gives you a more healthy golden glow than the sun.

12 Jan 2011

Discovery Labs regains compliance with Nasdaq Minimum Bid Price Rule

Discovery Laboratories, Inc. announced today that, on January 11, 2011, a NASDAQ Listing Qualifications Panel determined that Discovery Labs has regained compliance with Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Rule") because its common stock has maintained a minimum closing bid price of $1.00 per share over a period of 10 consecutive business days ending on January 10, 2011.

12 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Merck and PAREXEL enter strategic alliance for biosimilars

Merck and PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that they have entered into an alliance by which PAREXEL will provide strategic access to global clinical development services for designated biosimilar candidates to Merck BioVentures.

From Parexel 12 Jan 2011

Affymetrix enters distribution agreement with Fisher Scientific for GeneAtlas System

Affymetrix, Inc. today announced that it has signed a distribution agreement with Fisher Scientific, Inc., part of Thermo Fisher Scientific, to distribute the GeneAtlas™ System and its related consumables through the Fisher Scientific channel throughout the United States and Canada.

From Thermo Fisher Scientific Inc. 12 Jan 2011

Affymetrix anticipates $85 million total revenue for fourth quarter 2010

Affymetrix, Inc. today announced that based on preliminary financial data, the Company expects to generate positive operating income and net income on a GAAP basis for the fourth-quarter of 2010. Total revenue for the fourth quarter is expected to be approximately $85 million and includes a $4.8 million milestone payment from a "Powered by Affymetrix" diagnostic partner.

12 Jan 2011

Peakdale receives CIR accreditation from French Ministry of Higher Education and Research

Peakdale Molecular, a leading discovery and research services company, announced today that it has received the CIR accreditation from the French Ministry of Higher Education and Research.

12 Jan 2011

CRF Health offers gold standard ePRO education, demonstrates commitment to advance paperless trials

CRF Health, a leading global provider of ePRO solutions for the Life Sciences Industry, today announced a series of upcoming conferences that will feature presentations by CRF Health's ePRO experts.

12 Jan 2011

CE mark approves Vitrolife's SpermFreeze Solution

SpermFreeze Solution, which is used for freeze storage of sperm, has obtained a CE mark and is thereby approved for sales within the European Economic Area.

12 Jan 2011

Scientists introduce DNA directly into cell nucleus using protein nanodisks

One of the challenges of gene therapy - a set of methodologies aimed at treating several nucleic acid diseases - is to assure that this material arrives directly to the nucleus of the cell without losing a substantial amount along the way and without producing any undesired side effects. With this aim, scientists experiment with the use of different types of vectors, molecules capable of transporting genetic material to the correct place.

12 Jan 2011

Life Technologies announces new DNA sequencing portfolio for lab research

Life Technologies Corporation today announced a series of new product innovations across the company's DNA sequencing portfolio. To date, most sequencing technologies have primarily addressed the needs of researchers in the highest throughput laboratories, limiting widespread accessibility of these powerful next-generation sequencing technologies.

12 Jan 2011

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

ALLOZYNE, Inc. announced today, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties.

11 Jan 2011

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Vical Incorporated today announced a new publication summarizing results from the company's completed trials of Allovectin-7 including systemic responses and an excellent safety profile in patients with metastatic melanoma.

11 Jan 2011

IDEX enters definitive merger agreement to acquire Microfluidics International

IDEX Corporation today announced that it has entered into a definitive merger agreement to acquire Microfluidics International Corporation for $1.35 per share, net to the seller in cash, and subject to adjustment as provided in the merger agreement. The transaction is expected to close in the first quarter of 2011.

11 Jan 2011

First-ever global definition of lupus flare

The Lupus Foundation of America (LFA) spearheaded a four-year worldwide initiative with more than 120 lupus experts from 11 countries, the pharmaceutical and biotechnology industries, and federal agencies, which resulted in the first-ever global definition of a lupus flare. The development of Lupus Foundation of America Flare Definition (LFA-Flare) helps to overcome long-standing barriers to the development of new, safe, and more tolerable treatments for lupus.

11 Jan 2011

Biotechnology News and Research

Transition of oncology programme into lead optimisation triggers EUR 2.0M milestone payment to Evotec

Antibiotic treatment may be sufficient to overcome River Blindness

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

FDA accepts to review Fibrocell Science's azficel-T drug

Fruit and vegetables gives more healthy golden glow than the sun

Discovery Labs regains compliance with Nasdaq Minimum Bid Price Rule

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Merck and PAREXEL enter strategic alliance for biosimilars

Affymetrix enters distribution agreement with Fisher Scientific for GeneAtlas System

Affymetrix anticipates $85 million total revenue for fourth quarter 2010

Peakdale receives CIR accreditation from French Ministry of Higher Education and Research

CRF Health offers gold standard ePRO education, demonstrates commitment to advance paperless trials

CE mark approves Vitrolife's SpermFreeze Solution

Scientists introduce DNA directly into cell nucleus using protein nanodisks

Life Technologies announces new DNA sequencing portfolio for lab research

ALLOZYNE completes AZ01 Phase IA clinical trial in relapsing remitting multiple sclerosis

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

IDEX enters definitive merger agreement to acquire Microfluidics International

First-ever global definition of lupus flare

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News